Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF FEBRUARY 26, 2015 FBO #4842
SOLICITATION NOTICE

A -- SPECIALIZED SUPPORT TO ADVANCE VACCINE DEVELOPMENT AGAINST DIARRHEAL DISEASES TO PROTECT THE WARFIGHTER

Notice Date
2/24/2015
 
Notice Type
Combined Synopsis/Solicitation
 
NAICS
561990 — All Other Support Services
 
Contracting Office
Department of the Navy, Bureau of Medicine and Surgery, U.S. Naval Medical Research Unit - 6 Peru, Unit 3230 Box 343, American Embassy, DPO AA 34031-0343, Lima, Non-U.S., 34031-0343, Peru
 
ZIP Code
00000
 
Solicitation Number
N44852_VACCINE_DEVEL_DIARR
 
Archive Date
3/13/2015
 
Point of Contact
Javier B. Gil, Phone: 0115116144152, Genaro M Vasquez, Phone: 0115116144128
 
E-Mail Address
javier.gil@med.navy.mil, martin.vasquez@med.navy.mil
(javier.gil@med.navy.mil, martin.vasquez@med.navy.mil)
 
Small Business Set-Aside
N/A
 
Description
SCOPE OF WORK The U.S. NAVAL MEDICAL RESEARCH UNIT 6 (NAMRU-6) in Lima, Peru is requiring the service of an international organization, hereafter referred to as "the contractor", to provide advanced technical expertise to support vaccine development efforts in enteric diseases. The contractor must have a long-term collaborative agreement with NAMRU-6 and demonstrated track record conducting studies of diarrheal diseases in Peru as shown through strong publication records in this field as well as a long-term research infrastructure in Peru. Under the terms of this contract, the contractor will provide advanced scientific guidance during the execution of non-human primate trials conducted at NAMRU-6. Specifically, the contractor will assist in the implementation of state-of-the-art laboratory assays to measure vaccine-induced immune responses and define immune correlates of mucosal immunity in the context of vaccine studies for enteric diseases. The contractor will provide a full-time post-doctoral fellow who will be relocated to Lima, Peru during the duration of this contract to conduct studies at NAMRU-6. The fellow must have a strong research background in microbiology and immunology and demonstrated experience in the development and validation of immunological assays using multicolor flow cytometer, ELISA and immunohistochemistry among others. Due to the scope of this work, it is required that the post-doctoral fellow must have previous experience on research using animal models of human diseases. DELIVERABLES: • Amend IACUC vaccination/challenge protocols for ETEC, Shigella, and Champylobacter to longitudinally collect an expanded set of non-invasive and invasive tissue samples to evaluate correlates of protective immunity in non-human primates. • Develop and validate immunological assays to assess mucosal immunity in the non-human primate model including flow cytometry, ELISA and ELISPOT for NHP vaccine development studies. • Develop standard operating procedures (SOP) for the aforementioned assays. SOPs will be incorporated into bi-annual reports detailing progress in assay development to the contractor and NAMRU-6. • Execution of assays for all samples to support the aforementioned animal protocols at NAMRU-6. Support data analysis of the results • Lead the preparation of reports and scientific manuscripts for publication. PERIOD: This contract will be executed from March 17, 2015 to February 14, 2016 BUDGET: Estimated amount for the total period is $49,905.00
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/notices/822e6d06d672a7902a1db402912f56f6)
 
Place of Performance
Address: NAMRU-6, AV. VENEZUELA CDRA. 36, BELLAVISTA CALLAO, PERU, LIMA, Peru
 
Record
SN03650076-W 20150226/150224235104-822e6d06d672a7902a1db402912f56f6 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.